With bucks from Pfiz­er added to their new round, Am­plyx steers a tricky course through PhII and a glob­al pan­dem­ic

Af­ter beef­ing up its pipeline last year with an in-li­cens­ing deal from No­var­tis, San Diego-based Am­plyx has lined up an ex­ten­sion of their C round, de­signed to pay their way through a slate of mid-stage tri­als putting their ex­per­i­men­tal drugs to the test in hu­mans. And this time they’re get­ting some bucks from Pfiz­er to pay for the next leg in the de­vel­op­ment process.

The new mon­ey — a $53 mil­lion add to the first tranche in 2017 — brings their C round to­tal to $90 mil­lion-plus, with Pfiz­er join­ing a syn­di­cate that in­cludes Sofinno­va Ven­ture Part­ners, with par­tic­i­pa­tion from ex­ist­ing in­vestors in­clud­ing New En­ter­prise As­so­ciates, Lund­beck­fonden Ven­tures, Ar­ix Bio­science, Pap­pas Cap­i­tal, River­Vest Ven­ture Part­ners, 3×5 Part­ners and Bio­Med Ven­tures. Adage Cap­i­tal was an­oth­er new in­vestor in the round, with Pfiz­er, which brings the biotech’s to­tal raise to date to $140 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER